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Abstract
Purpose The objective of this study is to analyse the relative survival with breast cancer in women diagnosed after new 
treatments were generalised and to ascertain the current effect that tumour characteristics such as grade, stage or subtype 
have on survival as well as the new AJCC-pathological prognostic score.
Methods The breast cancer MCC-Spain follow-up study is a prospective cohort study of 1685 incident breast cancer cases. 
Women between 20 and 85 years old were recruited between the years 2008 and 2013 in 18 hospitals located in 10 Spanish 
provinces and they have been followed until 2017/2018. Relative survival was estimated after 3, 5 and 8 years of follow-up 
using Ederer II method. In addition, Weibull regression adjusted by age, hospital, grade and stage was used to investigate 
prognosis factors.
Results Among components of TNM staging system, tumour size greater than 50 mm (i.e. T3 or T4) more than doubled the 
risk of dying, while N3 nodal involvement and presence of metastasis had a huge effect on mortality. The AJCC pathologi-
cal prognostic score strongly correlated with survival; thus, hazard ratios increased as the score rose, being 2.31, 4.00, 4.94, 
7.92, 2.26, 14.9 and 58.9 for scores IB, IIA, IIB, IIIA, IIIB, IIIC and IV, respectively.
Conclusion Both TNM staging and histological/molecular biomarkers are associated with overall survival in Spanish women 
with breast cancer; when both are combined in the AJCC pathological prognosis score, the prognostic value improved with 
risk indices that increased rapidly as the pathological prognosis score increased
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Introduction
Breast cancer (BC) is the most frequent cancer and the fourth 
cause of death by cancer in women in developed countries 
[1]. Rates of survival with breast cancer have increased 
significantly all over the world in the past decades [2]. In 
Spain, it has been estimated that 32,825 new BC cases were 
diagnosed in 2018, with an incidence rate (Age-standardised 
[World]) of 75.4 cases per 100,000 women-years [3]. Main 
factors associated with prognosis in breast cancer are stage 
(enclosing tumour size and local infiltration, lymph nodes 
and metastasis), tumour grade of differentiation, histologi-
cal type and presence/absence of hormone and Her2/neu 
receptors [2].
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Although paclitaxel has been available since 1993, breast 
cancer treatment has considerably improved from 1995 
onwards as conservative surgery has become widely per-
formed. Systemic therapy has switched from CMF (cyclo-
phosphamide, methotrexate and 5-fluorouracil) to regimens 
containing anthracycline [4], routine searches for oestrogen 
and progesterone receptors has allowed for the introduction 
of tamoxifen, as well as identification of tumours positive 
to Her2/neu has enabled targeted therapy with trastuzumab 
[5], which was authorised in the European Union on August 
28, 2000. In this regard, identification of intrinsic subtypes 
(i.e. luminal A, luminal B, Her2-positive and basal-like) has 
allowed for agreement in general recommendations for first-
line therapy in early-stage breast cancer [6]. Survival has 
thus enhanced and 5-year survival is now around 85% [7–9]. 
In spite of the improvement in systemic therapy, tumour 
stage remains a key prognosis factor in breast cancer patients 
[10], which reinforces the relevance of early diagnosis. The 
American Joint Committee for Cancer (AJCC) has recently 
suggested a pathological prognostic score combining tumour 
stage, grade and hormonal/Her2 receptors [11], which has 
been proved effective as survival predictor [12, 13].
Studies carried out in population-based cancer registries 
covering 17% of the Spanish population reported that women 
with BC diagnosed in Spain had 86.0% 5-year age-adjusted 
relative survival if diagnosed between 1995 and 1999 [7, 14] 
with no improvements for women diagnosed from 2000 to 
2007 [7]. That study, however, included women diagnosed 
well before the extension of anthracycline-based chemother-
apy and the introduction of endocrine therapy with tamox-
ifen and anti-Her2 treatment with trastuzumab. The main 
goal in this study is to analyse the relative survival with BC 
in women diagnosed in 2008–2013—after new treatments 
were generalised—and to ascertain the current effect that 
tumour characteristics such as grade, stage or subtype have 




The breast cancer MCC-Spain follow-up study is a prospec-
tive cohort study of incident breast cancer cases diagnosed 
between 2008 and 2013 in 18 hospitals located in 10 Spanish 
provinces (Asturias, Barcelona, Cantabria, Girona, Gipuz-
koa, Huelva, León, Madrid, Navarra and Valencia). 1738 
women between 20 and 85 years old with newly diagnosed 
primary breast cancer were recruited in the context of a 
case–control study. The identification of incident cases was 
carried out by active search through periodic visits to the 
relevant hospital departments (i.e. gynaecology, oncology, 
general surgery, radiotherapy and pathology departments). 
All the cases that were included had histological confirma-
tion and included all the malignant BC (International Classi-
fication of Diseases 10th Revision (ICD-10) [15] code C50) 
and frequent breast cancers in situ (ICD-10: D05.1, D05.7), 
without a malignant history of BC, diagnosed between 2008 
and 2013 in the selected hospitals. Patients were residing in 
the catchment areas of hospitals for at least 6 months before 
recruitment. A detailed description of methods and sam-
ple characteristics has been published elsewhere [16, 17] 
and then, 98% recruited patients have been followed until 
2017/2018 (N = 1685). Only patients signing an informed 
consent were recruited; the informed consent also asked 
them for their permission for later consulting their medical 
records during the follow-up.
Information obtained at recruitment
When the patients were recruited, medical records were 
reviewed in order to gather information on age, date of 
diagnosis, tumour characteristics, including tumour size, 
lymph nodes, presence of metastases, grade of differentia-
tion. Furthermore, oestrogen (ER), progesterone (PgR) and 
human epidermal growth factor receptor 2 (HER2) status 
were assessed and then classified as positive (+), negative 
(−) and unknown. Specifically, ER and PgR were considered 
positive if 1% or more of neoplastic cells showed nuclear 
immunohistochemical (IHC) staining. HER2 was considered 
positive (overexpressed) if graded 3 + on IHC performed, 
and all other grades (0 to 2 +) were considered negative 
unless fluorescence in situ hybridization of 2 + cases con-
firmed increased gene copy number. Molecular subtypes of 
breast carcinoma is classified into luminal A (ER + and / 
or PR + , HER2-, Ki-67 < 14%), luminal B (ER + and / or 
PR + , HER2-, or ER + and / or PR + , HER2-, Ki-67 ≥ 14%), 
HER2 + (ER-, PR-, HER2 +) and basal-like or triple negative 
is a tumour which does not meet any pathologic criteria for 
positivity of oestrogen receptor, progesterone receptor, or 
ERBB2 (ER-, PR- and HER2-) [6]. Tumour stage was based 
on the AJCC standards [18]. Tumour size was classified as 
T1: ≤ 2 cm, T2: > 2 cm and ≤ 5 cm, T3: > 5 cm, T4: any size 
with direct extension to chest wall and/or skin; lymph node 
involvement was classified as N0: no pathologically proven 
positive lymph nodes, N1: 1–3 positive nodes, N2: 4–9 
positive nodes, N3: ≥ 10 positive nodes. Tumour grade was 
categorised as I: well differentiated, II: moderately differen-
tiated, III: poorly differentiated, according to the modified 
Bloom and Richardson grading system [19]; when Bloom 
and Richardson grade was unavailable, other similar clas-
sifications were used as it has been proved they are highly 
reliable [20]. First-line therapy was also recorded, includ-
ing type of surgery (conservative or mastectomy), margins 
(free or invaded), chemotherapy regime, radiotherapy, 
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endocrine therapy, Her2-targeted therapy; for all systemic 
therapies, whether they were adjuvant or neoadjuvant was 
also recorded.
Follow‑up
In 2017 and 2018, medical records were reviewed to obtain 
the last date the patient was attended to in t the health system 
and to ascertain current patient’s vital status. For patients 
that had not have been at hospital in the 3 months before 
their medical record review, the National Death Index 
(Índice Nacional de Defunciones) was consulted [21]. This 
index is a database recording date of death for all people 
who have died in Spain; it is hosted on the Ministry of 
Health web page and can only be accessed with specific 
authorisation for research purposes. Last date of search in 
the National Death Index was in December 2018.
Statistical analysis
Deaths by any cause were considered events and patients 
alive in their last contact with hospital and not included in 
the National Death Index were considered censored. Time 
of follow-up was considered as the time from diagnosis to 
death or to the last contact in hospital in alive patients. Rela-
tive survival, defined as the ratio of the observed survival 
in our study population and the expected survival in general 
population Spanish women with the same age as cases in 
the year of diagnosis, was estimated using Ederer II method 
[22]; for this purpose, age-specific mortality rates from 
2007 to 2018 obtained from the Spanish National Institute 
for Statistics (INE) were used as reference. 3-, 5- and 8-year 
survival Kaplan–Meier estimates were obtained. Weibull 
regression adjusting by age, hospital, grade and stage was 
used to investigate prognosis factors; its results are displayed 
as hazard ratios with their 95% confidence intervals. Groups 
that included less than 25 people were excluded from this 
analysis. Stata 14/SE package was used in the analyses.
Results
Characteristics of patients
We followed 1685 women out of 1738 breast cancer patients 
(98%), who had primary breast cancer between 2007 and 
2013. Patient-years of follow-up were 10,931 person-years. 
The maximum period for breast cancer follow-up was nine 
and a half years (from 13th July 2007 to 22nd March 2018) 
and 206 patients died in the follow-up; 5-year survival was 
90.7%.
The mean age at diagnosis was 56.5 ± 12.6-year-old and 
65% were postmenopausal. Other main characteristics of the 
patients are shown in supplementary Table 1.
Tumour characteristics
Regarding the characteristics of the tumours, the most usual 
histological type was ductal (75.7%), followed by lobular 
(6.5%). About half of cancers were T1 (52%) and lymph 
node negatives (52%). Only 42 women (2.5%) had metasta-
sis at the time of diagnosis.
Concerning intrinsic subtypes, 997 (59.2%) could be clas-
sified as luminal A-like, 331 (19.6%) as luminal B-like, 81 
(4.8%) as Her2 (non-luminal)-like and 130 (7.7%) as basal-
like. Grade of differentiation could not be obtained from 
medical records in 481 patients (28.5%). Almost 31% of the 
cancers were moderately differentiated while poorly differ-
entiated accounted for about 21% cancers. Hormone recep-
tor status was available for most cases; 83% were oestrogen 
receptor positive, 73% progesterone positive and 17.4% were 
Her2 positive (Table 1).
Relative survival
5-year relative survival with breast cancer was 93% (95% 
CI 92 – 94) (Fig. 1a). Table 1 shows 3-, 5- and 8-year rela-
tive survival according to tumour characteristics. Women 
diagnosed in stage I had the same survival probability than 
women with the same age without breast cancer (i.e. 100% 
relative survival) even after 8 years of follow-up. At the 
same time, relative survival decreased with follow-up time 
in women diagnosed in more advanced stages: 3-, 5- and 
8-year relative survival were 98%, 95% and 93% for breast 
cancer diagnosed in stage II, 94%, 88% and 81% in women 
diagnosed in staged III and 63%, 40% and 24% in those 
diagnosed in staged IV (Table 1 and Fig. 1b). Relative sur-
vival also decreased as grading got less differentiated [8-year 
relative survival: 99% in well differentiated tumours, 93% in 
moderately differentiated and 88% in poorly differentiated 
(Table 1 and Fig. 1c)]. Relative survival after 8 years of 
follow-up was 94% for luminal A-like breast cancers, 88% 
for luminal B-like, 82% for Her2 non-luminal) and 74% for 
basal-like cancers (Table 1 and Fig. 1d).
Prognostic factors on overall mortality
Age, hospital, stage and grade-adjusted hazard ratios on 
association between survival and tumour characteristics 
and first-line treatment are displayed in Table 2. Age, 
premenopausal status, tumour size, nodal infiltration and 
presence of metastasis were significantly associated with 
overall mortality. Hazard ratios increased with tumour 
stage, being 1 (reference) for T1 and 1.62 (1.04 – 2.52) 
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and 2.04 (1.13 – 3.68) for T2, T3, respectively. Breast 
cancers negative for oestrogen or progesterone receptors 
behaved worse than their opposite. Luminal A- like and 
luminal B-like tumours had similar prognosis; hazard for 
Her2 (non-luminal) cancers were 50% higher than for 
luminal A-like (hazard ratio = 1.50; 95% CI 0.87 – 2.59), 
and basal-like tumour’s hazard was three times that of 
luminal A-like (hazard ratio = 3.50; 95% CI 2.31 – 5.30). 
Grading showed a dose–response association with mortal-
ity, with hazard ratios 1 (reference) for well differentiated 
cancers, 1.48 (0.86 – 2.54) for moderately differentiated 
and 2.42 (1.41 – 4.17) for poorly differentiated. To further 
explore whether intrinsic subtype adds prognosis value to 
tumour stage, we studied the effect of stage by stratifying 
for intrinsic subtype; results in Fig. 2a show that higher 
stages had higher hazard ratios, whatever the intrinsic 
subtype. However, when stratifying the effect of intrinsic 
subtype for tumour stage, we found that intrinsic subtype 
had no effect at all in patients in stage I, while Her2 (non-
luminal) and basal-like tumours had worse prognosis than 
luminal-like tumours in patients with stage II and, espe-
cially, stages III and IV (Fig. 2b).
Table 1  Relative survival probability 3, 5 and 8 years after breast cancer diagnosis according to tumour characteristics
ONI Otherwise non-identified, Luminal ONI hormonal receptors positive, Her2 missing, Non-luminal ONI hormonal receptors negative, Her2 
missing
Variable Category N (%) 3-year 5-year 8-year
Survival (95% CI) Survival (95% CI) Survival (95% CI)
Histology Ductal 1276 (75.73) 97 (95–98) 93 (92–95) 91 (88–93)
Lobular 110 (6.53) 95 (88–98) 89 (80–94) 87 (76–94)
Other 299 (17.74) 100 (98–101) 97 (94–99) 97 (92–100)
Tumour size T1 876 (51.99) 100 (99–101) 98 (97–99) 97 (95–99)
T2 424 (25.16) 96 (93–98) 91 (87–94) 87 (81–91)
T3 73 (4.33) 88 (77–94) 75 (63–85) 71 (58–81)
T4 39 (2.31) 74 (56–86) 59 (41–74) 59 (40–75)
Tis 109 (6.47) 101 (101–101) 102 (102–102) 100 (91–103)
Missing 141 (8.37) 93 (86–97) 87 (80–93) 81 (69–90)
Node infiltration N0 877 (52.05) 100 (99–100) 97 (95–99) 98 (96–100)
N1 441 (26.17) 97 (95–99) 94 (91–96) 90 (85–94)
N2 142 (8.43) 93 (86–97) 85 (77–91) 78 (68–86)
N3 49 (2.91) 81 (67–91) 77 (61–87) 61 (40–78)
Missing 176 (10.45) 92 (86–96) 88 (81–93) 79 (69–87)
Tumour stage 0 112 (6.65) 100 (95–101) 101 (96–102) 98 (89–102)
I 594 (35.25) 101 (99–101) 99 (97–101) 100 (97–102)
II 498 (29.55) 98 (96–100) 95 (92–97) 93 (88–96)
III 187 (11.10) 94 (89–97) 88 (82–93) 81 (72–88)
IV 42 (2.49) 63 (46–77) 40 (24–55) 24 (11–40)
Oestrogen receptor Positive 1398 (82.97) 99 (98–100) 96 (94–97) 93 (91–95)
Negative 244 (14.48) 86 (81–90) 81 (75–86) 80 (73–85)
Progesterone receptor Positive 1237 (73.41) 100 (98–100) 97 (95–98) 95 (92–97)
Negative 401 (23.80) 90 (86–93) 85 (80–88) 81 (76–85)
Her2 Negative 1250 (74.18) 97 (96–98) 93 (92–95) 91 (88–93)
Positive 294 (17.45) 97 (94–99) 93 (89–96) 89 (84–93)
Intrinsic subtype Luminal A 997 (59.17) 100 (98–100) 96 (94–98) 94 (92–97)
Luminal B 331 (19.64) 97 (95–99) 94 (90–97) 88 (83–93)
Her2 81 (4.81) 94 (86–99) 87 (76–93) 82 (70–91)
Basal-like 130 (7.72) 78 (70–85) 74 (65–81) 74 (64–82)
Luminal ONI 91 (5.40) 100 (94–101) 101 (95–102) 101 (92–104)
Grade I: Well differentiated 329 (19.53) 100 (98–101) 99 (96–101) 99 (95–102)
II: Moderately differentiated 520 (30.86) 100 (98–101) 95 (92–97) 93 (89–96)
III: Poorly differentiated 355 (21.07) 93 (89–95) 90 (86–94) 88 (83–92)
Missing 481 (28.55) 96 (93–98) 91 (88–94) 88 (83–91)
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Pathologic prognostic score in women 
without neoadjuvant therapy
Figure 3 displays the association between the AJCC- Patho-
logic Prognostic Score and overall survival in women with-
out neoadjuvant therapy. Hazard ratios stepped up as the 
score rose, being 2.31, 4.00, 4.94, 7.92, 2.26, 14.9 and 58.9 
for scores IB, IIA, IIB, IIIA, IIIB, IIIC and IV, respectively. 
These results are somewhat limited because of their wide 
confidence intervals. This information appears stratified by 
menopausal status in supplementary material, where hazard 
ratios increased faster in premenopausal women (Supple-
mentary Table 2).
First‑line treatment for patients
Table 3 shows the characteristics of the treatment. Conserva-
tive surgery was performed in 1231 (73.1%) patients and 
mastectomy in the remaining 454 (26.9%). Surgical margins 
were negative in 66% patients. Radiotherapy was used in 1158 
women (68.7%), while adjuvant or neoadjuvant chemotherapy 
was administered to 50.13% patients. Adjuvant or neoadjuvant 
hormone therapy was used in 1023 women (60.7%), immu-
notherapy in 11.1% and Her2-targeted therapy in 152 patients 
(9.0%).
Hazard ratios on association between survival and first-line 
treatment are displayed in Table 4. Type of surgery (mastec-
tomy/conservative surgery) and surgical margins were not 
associated with survival. Among systemic treatments, adju-
vant therapy (whether chemo-, radio- or hormone-therapy) 
was associated with lower mortality and both neoadjuvant 
and palliative treatment were associated with worse progno-
sis (Table 4).
Fig. 1  Relative survival in Spanish women with breast cancer: a Overall survival, b survival according to TNM staging, c survival according to 
grading, d survival according to intrinsic subtype
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Discussion
In spite of recent improvements in breast cancer systemic 
therapy, our results confirm that tumour stage and grad-
ing are major prognosis factors regarding overall survival 
with breast cancer. Among components of TNM stag-
ing system, tumour size greater than 50 mm (i.e. T3 or 
T4) more than doubled the risk of dying, while N3 nodal 
involvement and presence of metastasis had a huge effect 
on mortality. The pathological prognostic score suggested 
by the AJCC in 2017 combining anatomic characteristics 
(i.e. TNM staging) with biological characteristics (i.e. 
grading and hormonal/Her2 receptors) strongly correlated 
with survival.
TNM staging has largely been the main factor regarding 
survival with breast cancer, which led the AJCC to suggest 
its Anatomic Stage Groups [11]. Our results on TNM com-
ponents are consistent with recent studies still proving that 
TNM classification is a main contributor to survival [10, 
23–25]. For instance, a large study with data from Nether-
lands Cancer Registry reported hazard ratios over 2.5 for T3 
or T4 tumours and 4.0 for N3 tumours in women diagnosed 
between 2006 and 2012. These hazard ratios were similar 
to those obtained in the same registry for women diagnosed 
Table 2  Characteristics of the 
tumour and their association 
with survival
Hazard ratios and 95% confidence intervals estimated via Weibull regression
*Hazard ratios adjusted for age, hospital, stage and grade
ONI otherwise not identified
Variable Category N (%) Hazard ratio (95% CI)* p
Histology Ductal 1276 (75.73) 1 (ref)
Lobular 110 (6.53) 1.12 (0.68 to 1.83) 0.666
Other 299 (17.74) 0.44 (0.26 to 0.72) 0.001
Tumour size T1 876 (51.99) 1 (ref)
T2 424 (25.16) 1.62 (1.04 to 2.52) 0.031
T3 73 (4.33) 2.04 (1.13 to 3.68) 0.018
T4 39 (2.31) 1.96 (0.98 to 3.91) 0.056
Tis 109 (6.47) 0.14 (0.02 to 0.91) 0.04
Missing 141 (8.37) 1.12 (0.61 to 2.06) 0.718
Node infiltration N0 877 (52.05) 1 (ref)
N1 441 (26.17) 1.16 (0.76 to 1.78) 0.481
N2 142 (8.43) 1.17 (0.58 to 2.36) 0.651
N3 49 (2.91) 1.73 (0.81 to 3.72) 0.158
Missing 176 (10.45) 1.15 (0.65 to 2.03) 0.641
Tumour stage 0 112 (6.65) 0.68 (0.26 to 1.81) 0.444
I 594 (35.25) 1 (ref)
II 498 (29.55) 2.30 (1.46 to 3.61)  > 0.001
III 187 (11.10) 4.23 (2.60 to 6.88)  > 0.001
IV 42 (2.49) 29.5 (16.9 to 51.6)  > 0.001
Oestrogen receptor Positive 1398 (82.97) 1 (ref)
Negative 244 (14.48) 2.31 (1.65 to 3.23)  > 0.001
Progesterone receptor Positive 1237 (73.41) 1 (ref)
Negative 401 (23.80) 2.13 (1.58 to 2.87)  > 0.001
Her2 Negative 1250 (74.18) 1 (ref)
Positive 294 (17.45) 0.79 (0.55 to 1.14) 0.209
Intrinsic subtype Luminal A 997 (59.17) 1 (ref)
Luminal B 331 (19.64) 1.16 (0.81 to 1.66) 0.429
Her2 81 (4.81) 1.50 (0.87 to 2.59) 0.143
Basal-like 130 (7.72) 3.50 (2.31 to 5.30)  > 0.001
Luminal ONI 91 (5.40) 0.20 (0.05 to 0.82) 0.026
Grade I: Well differentiated 329 (19.53) 1 (ref)
II: Moderately differentiated 520 (30.86) 1.48 (0.86 to 2.54) 0.157
III: Bad differentiated 355 (21.07) 2.42 (1.41 to 4.17) 0.001
missing 481 (28.55) 2.31 (1.27 to 4.18) 0.006




Fig. 2  Hazard ratios for overall survival showing the interaction between TNM stage and intrinsic subtype. a Hazard ratios for TNM stage strati-
fied by intrinsic subtype, b hazard ratios for intrinsic subtype stratified by TNM stage
Fig. 3  Kaplan–Meier survival 
estimates according to the 
AJCC pathological prognostic 
score
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Table 3  First-line treatment and relative survival probability 3, 5 and 8 years after diagnosis
Variable Category N (%) 3-year 5-year 8-year
Survival (95% CI) Survival (95% CI) Survival (95% CI)
Surgery Conservative 1231 (73.06) 98 (97–99) 95 (94–97) 93 (91–95)
Mastectomy 454 (26.94) 94 (91–97) 89 (86–92) 87 (82–91)
Surgical margins Negative 1104 (65.52) 98 (97–99) 95 (93–97) 94 (91–96)
Positive 244 (14.48) 100 (97–101) 98 (94–100) 95 (89–98)
missing 337 (20.00) 92 (88–95) 87 (82–90) 82 (76–87)
Chemotherapy No 817 (48.49) 98 (97–100) 96 (94–98) 95 (91–97)
Neoadjuvant 180 (10.68) 95 (90–97) 87 (81–92) 83 (76–88)
Adjuvant 663 (39.35) 99 (97–100) 96 (94–98) 93 (90–96)
Palliative 25 (1.48) 40 (21–59) 16 (5–33)
Radiotherapy No 334 (22.45) 95 (92–98) 91 (87–95) 88 (81–93)
Neoadjuvant 5 (0.34) 61 (13–89) 21 (1–60)
Adjuvant 1128 (75.81) 100 (99–100) 97 (96–98) 95 (93–97)
Palliative 21 (1.41) 31 (13–52) 16 (4–35)
Immunotherapy No 1498 (88.90) 98 (97–99) 95 (93–96) 93 (90–95)
Neoadjuvant 27 (1.60) 90 (70–97) 75 (54–88) 67 (45–83)
Adjuvant 144 (8.55) 98 (94–100) 95 (89–98) 92 (85–97)
Palliative 16 (0.95) 41 (17–64) 28 (9–51)
Endocrine therapy No 662 (39.29) 94 (91–96) 90 (87–92) 86 (82–90)
Neoadjuvant 19 (1.13) 103 (103–103) 76 (48–93) 72 (40–94)
Adjuvant 985 (58.46) 100 (99–101) 98 (97–99) 97 (94–99)
Palliative 19 (1.13) 61 (35–80) 26 (9–49)
Table 4  First-line treatment and 
their association with survival
Hazard ratios and 95% confidence intervals estimated via Weibull regression
*Hazard ratios adjusted for age, hospital, stage and grade
Variable Category N (%) Hazard ratio (95% CI) * p
Surgery Conservative 1231 (73.06) 1 (ref)
Mastectomy 454 (26.94) 0.83 (0.56 to 1.22) 0.339
Surgical margins Negative 1104 (65.52) 1 (ref)
Positive 244 (14.48) 0.84 (0.50 to 1.42) 0.518
Missing 337 (20.00) 1.03 (0.67 to 1.56) 0.905
Chemotherapy No 817 (48.49) 1 (ref)
Neoadjuvant 180 (10.68) 1.18 (0.72 to 1.91) 0.514
Adjuvant 663 (39.35) 0.60 (0.40 to 0.89) 0.010
Palliative 25 (1.48) 8.44 (4.61 to 15.4)  < 0.001
Radiotherapy No 334 (22.45) 1 (ref)
Neoadjuvant 5 (0.34) 6.05 (1.88 to 19.5) 0.003
Adjuvant 1128 (75.81) 0.44 (0.30 to 0.65)  < 0.001
Palliative 21 (1.41) 5.31 (2.57 to 11.0)  < 0.001
Immunotherapy No 1498 (88.90) 1 (ref)
Neoadjuvant 27 (1.60) 1.79 (0.87 to 3.67) 0.113
Adjuvant 144 (8.55) 0.83 (0.48 to 1.44) 0.518
Palliative 16 (0.95) 5.22 (2.57 to 10.6)  < 0.001
Endocrine therapy No 662 (39.29) 1 (ref)
Neoadjuvant 19 (1.13) 1.17 (0.50 to 2.76) 0.719
Adjuvant 985 (58.46) 0.51 (0.37 to 0.71)  < 0.001
Palliative 19 (1.13) 2.18 (1.05 to 4.56) 0.037
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between 1999 and 2005 [10], which reinforces TNM staging 
relevance for survival has not changed with recent treatment 
improvements, thus strengthening the importance of early 
diagnosis.
Recent developments, however, have focused on tumour 
biology, making the identification of breast cancer subtypes 
via differentiation grade or presence of hormonal and Her2/
neu receptors possible, heading to specific therapies accord-
ing to tumour histological and molecular characteristics 
[6, 26–28]. Our results also confirmed higher survival for 
women with breast cancer positive to either oestrogen or 
progesterone receptors and negative to HER2 receptors, as 
well as worsening prognostic as grading increased from well 
to poorly differentiated tumour. In this regard, the new AJCC 
Pathological Prognostic Score [11] has been suggested by 
combining both anatomic staging and biological markers, 
thus refining the previous AJCC Anatomic Stage Groups 
[12], which is now intended only for regions were biological 
markers are not routinely available [11]. In our cohort, the 
AJCC Pathological Prognostic Score had large prognostic 
value with hazard ratios swiftly rising as the Pathological 
Prognostic Score increased. In addition, this score presents 
a higher predictive ability in premenopausal women. This 
can be explained by (i) the rate at which the cancer devel-
ops—tumours could be faster and receive poorer prognosis 
in premenopausal women—and (ii) the fact that a younger 
woman, i.e. premenopausal, with breast cancer is more likely 
to die because of the tumour itself, as opposed to postmeno-
pausal women, who have more chances to die due to other 
causes. Of note, the analysis of Pathological Prognostic 
Score should have been restricted to women without neo-
adjuvant therapy as this score is based on the pathological 
TNM staging, which is obtained after surgery.
Adjuvant chemotherapy, radiotherapy or endocrine 
therapy was associated with better prognosis in our cohort, 
which agrees with previous reports [4, 29–31]. Neoadju-
vant therapy, however, was associated with lower survival. 
Results on systemic therapy—survival relationship can-
not be straight forwardly interpreted as, even after adjust-
ing for stage and grade, there is still room for confounding 
by indication as women with more severe cancer are more 
likely treated with more aggressive therapies. For instance, 
neoadjuvant therapy is not usually recommended for low 
proliferating cancers and hormone receptor-positive, HER2-
negative, grading I–II cancers [26]; therefore, its high hazard 
ratios could be due to residual confounding as it is frequently 
indicated in cancers with worse prognostic.
Our study has some limitations. Firstly, the sample size—
although enough for general results—is small for studying 
specific subgroups or interactions. Secondly, basal infor-
mation was obtained from medical records, which could 
have partial information on some variables, leading to some 
amount of missing data. On this subject, it is noteworthy 
that missing categories did not follow a clear pattern in our 
results as missing data in TNM components behaved almost 
as the reference category (i.e. good prognostic), while 
missing data in grading performed as poorly differentiated 
tumours. Therefore, it is not possible for us to attribute any 
data omission in medical records to its irrelevance. Thirdly, 
our sample could be biased towards cancers with better prog-
nostic as women with advanced disease could have refused 
to participate, thus underrepresenting women in stage IV; 
had this occurred, it could have overestimated relative sur-
vival; however, this problem should have not biased hazard 
ratios estimates. Finally, the multicentric design of our study 
is both a limitation and a strength. A limitation as routine 
clinical practice could vary from hospital to hospital, eventu-
ally increasing random variation; we dealt with this problem 
by adjusting all our analyses for hospital. Nevertheless, it is 
also a strength as it obtained a fair representation of usual 
clinical practice in Spain about 2008–2013. An additional 
strength is the active prospective follow-up, carried out via 
three complementary sources: medical records, phone calls 
to the patient and National Death Index consultation.
Conclusions
In conclusion, both TNM staging and histological/molecular 
biomarkers are associated with overall survival in Spanish 
women with breast cancer; when both are combined in the 
AJCC Pathological Prognostic Score, its prognostic value 
vastly improved in women without neoadjuvant therapy.
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